Lebwohl M, Bachelez H, Gordon K, Wu T, Chen M, Kaplan B, Papp K. Maintenance of Clinical Response With Continued Risankizumab Treatment for Moderate-to-Severe Psoriasis Through 304 Weeks: Interim Analysis of the LIMMitless Open-Label Extension Study. J of Skin [Internet]. 2023Nov.13 [cited 2024Jul.22];7(6):s258. Available from: https://jofskin.org/index.php/skin/article/view/2428